Experimental and clinical investigation on oxiconazole.
A new antimycotic imicazole drug, oxiconazole, used both in vitro and in vivo in the treatment of 212 cases of tinea corporis, tinea cruris and tinea pedis is reported. In vitro, it shows marked antimycotic effect against 24 strains of pathogenic fungi except those of Wangiella dermatitides and 3 strains of Aspergilli. The minimal inhibition concentration (MIC) to Epidermophyton floccosum and Candida guilliermondi are 1 microgram/ml and 0.5 microgram/ml. The cure rate of 2% cream of oxiconazole in 124 cases of tinea corporis and tinea cruris is 90.3%, and in 88 cases of tinea pedis, 89.78%.
Wu
S X
SX
Shen
Y N
YN
Yan
N
N
Guo
N R
NR
Liu
L L
LL
Yang
J Q
JQ
D000293:Adolescent; D000328:Adult; D000935:Antifungal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D005260:Female; D005658:Fungi / Q000187:drug effects; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D014005:Tinea / Q000188:drug therapy*; D014008:Tinea Pedis / Q000188:drug therapy
D000935:Antifungal Agents; D007093:Imidazoles; C022155:oxiconazole